Compare Eli Lilly And Co (LLY) vs Marathon Digital Holdings Inc (MARA) Price & Performance

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

Marathon Digital Holdings (MARA) trades at $9.60, down 7.34% on the day, reflecting ongoing volatility. The stock shows mixed signals with bearish technical indicators but positive analyst sentiment. Fundamentally, the company reported significant losses with a net income margin of -429.71% in 2026, though revenue remains substantial at $804 million. Recent news highlights stock movements tied to Bitcoin price fluctuations and analyst coverage, including a Hold rating from Clear Street with a $10 price target.

The outlook remains cautious due to persistent losses and high volatility, though analyst consensus suggests potential upside to $13.25. Key risks include operational cash burn, competitive pressures, and regulatory uncertainty. Investment opportunity exists if the company can improve profitability and manage costs effectively, but current financial health warrants careful monitoring.